JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Strona główna・Stock List・Ascendis Pharma A/S

Ascendis Pharma A/S

Closed

SectorHealthcare

229.21 1.91

Buy Sell

Overview

Share price change

24h

Current

Min

221.26

Max

229.35

Key metrics
By Trading Economics
Income	28M -33M
Sales	32M 245M
Profit margin	-13.56
Employees	1,189
EBITDA	68M 15M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+31.83% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1.5B 15B
Previous open	227.3
Previous close	229.21

News Sentiment

By Acuity

50%

186 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A/S Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 kwi 2026, 19:19 UTC

Acquisitions, Mergers, Takeovers

Intertek Group Rejects EQT's Revised Offer

24 kwi 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Scoring the Cook Era -- Barrons.com

24 kwi 2026, 20:51 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Financial Services Roundup: Market Talk

24 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 kwi 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 20:09 UTC

Earnings

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 kwi 2026, 19:48 UTC

Market Talk

Major News Events

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 kwi 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 kwi 2026, 19:22 UTC

Earnings

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 kwi 2026, 19:06 UTC

Earnings

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 kwi 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 kwi 2026, 18:30 UTC

Acquisitions, Mergers, Takeovers

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 kwi 2026, 18:28 UTC

Acquisitions, Mergers, Takeovers

Intertek Rejects Revised EQT Offer

24 kwi 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 kwi 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 kwi 2026, 17:42 UTC

Earnings

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 kwi 2026, 17:28 UTC

Earnings

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 kwi 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 kwi 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24 kwi 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 kwi 2026, 17:09 UTC

Market Talk

Earnings

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 kwi 2026, 17:09 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 17:06 UTC

Earnings

Acquisitions, Mergers, Takeovers

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 kwi 2026, 16:51 UTC

Earnings

Acquisitions, Mergers, Takeovers

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 kwi 2026, 16:20 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

24 kwi 2026, 16:20 UTC

Market Talk

Major News Events

Financial Services Roundup: Market Talk

24 kwi 2026, 16:20 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

24 kwi 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Peer Comparison

Price change

Ascendis Pharma A/S Forecast

Price Target

By TipRanks

31.83% upside

12 Months Forecast

Average 296.62 USD 31.83%

High 342 USD

Low 255 USD

Based on 13 Wall Street analysts offering 12 month price targets forAscendis Pharma A/S - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Ascendis Pharma A/S - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

186 / 348 Ranking in Healthcare

Financials

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.